Short Interest in Caring Brands, Inc. (NASDAQ:CABR) Grows By 278.7%

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 20,796 shares, an increase of 278.7% from the May 14th total of 5,492 shares. Based on an average daily trading volume, of 101,232 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.3% of the shares of the stock are short sold.

Institutional Investors Weigh In On Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new stake in Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned about 0.25% of Caring Brands at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Caring Brands in a report on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Caring Brands has a consensus rating of “Sell”.

Caring Brands Stock Down 0.5%

Shares of CABR traded down $0.01 during midday trading on Thursday, hitting $1.10. The company’s stock had a trading volume of 26,545 shares, compared to its average volume of 118,874. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 5.62. Caring Brands has a one year low of $0.71 and a one year high of $5.35. The company has a market cap of $9.96 million and a PE ratio of -1.71. The company’s fifty day moving average price is $1.11.

Caring Brands (NASDAQ:CABR) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.